[The medicinal treatment of COVID-19: a brief update].
Identifieur interne : 000918 ( Main/Exploration ); précédent : 000917; suivant : 000919[The medicinal treatment of COVID-19: a brief update].
Auteurs : Mark G J. De Boer [Pays-Bas] ; Emilie M. Gieling [Pays-Bas] ; Paul D. Van Der Linden ; Bhanu N M. Sinha [Pays-Bas] ; Albert M. VollaardSource :
- Nederlands tijdschrift voor geneeskunde [ 1876-8784 ] ; 2020.
Descripteurs français
- KwdFr :
- AMP (analogues et dérivés), AMP (pharmacologie), AMP (usage thérapeutique), Alanine (analogues et dérivés), Alanine (pharmacologie), Alanine (usage thérapeutique), Anti-inflammatoires (pharmacologie), Anti-inflammatoires (usage thérapeutique), Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Essais contrôlés randomisés comme sujet (MeSH), Glucocorticoïdes (pharmacologie), Glucocorticoïdes (usage thérapeutique), Humains (MeSH), Hydroxychloroquine (pharmacologie), Hydroxychloroquine (usage thérapeutique), Pays-Bas (épidémiologie), Repositionnement des médicaments (méthodes), Repositionnement des médicaments (normes), Résultat thérapeutique (MeSH).
- MESH :
- analogues et dérivés : AMP, Alanine.
- méthodes : Repositionnement des médicaments.
- normes : Repositionnement des médicaments.
- pharmacologie : AMP, Alanine, Anti-inflammatoires, Antiviraux, Glucocorticoïdes, Hydroxychloroquine.
- usage thérapeutique : AMP, Alanine, Anti-inflammatoires, Antiviraux, Glucocorticoïdes, Hydroxychloroquine.
- épidémiologie : Pays-Bas.
- Essais contrôlés randomisés comme sujet, Humains, Résultat thérapeutique.
- Wicri :
- geographic : Pays-Bas.
English descriptors
- KwdEn :
- Adenosine Monophosphate (analogs & derivatives), Adenosine Monophosphate (pharmacology), Adenosine Monophosphate (therapeutic use), Alanine (analogs & derivatives), Alanine (pharmacology), Alanine (therapeutic use), Anti-Inflammatory Agents (pharmacology), Anti-Inflammatory Agents (therapeutic use), Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), COVID-19 (drug therapy), COVID-19 (epidemiology), Drug Repositioning (methods), Drug Repositioning (standards), Glucocorticoids (pharmacology), Glucocorticoids (therapeutic use), Humans (MeSH), Hydroxychloroquine (pharmacology), Hydroxychloroquine (therapeutic use), Netherlands (epidemiology), Randomized Controlled Trials as Topic (MeSH), SARS-CoV-2 (drug effects), Treatment Outcome (MeSH).
- MESH :
- chemical , analogs & derivatives : Adenosine Monophosphate, Alanine.
- chemical , pharmacology : Adenosine Monophosphate, Alanine, Anti-Inflammatory Agents, Antiviral Agents, Glucocorticoids, Hydroxychloroquine.
- chemical , therapeutic use : Adenosine Monophosphate, Alanine, Anti-Inflammatory Agents, Antiviral Agents, Glucocorticoids, Hydroxychloroquine.
- geographic , epidemiology : Netherlands.
- drug effects : SARS-CoV-2.
- drug therapy : COVID-19.
- epidemiology : COVID-19.
- methods : Drug Repositioning.
- standards : Drug Repositioning.
- Humans, Randomized Controlled Trials as Topic, Treatment Outcome.
Abstract
Much has changed in the medical treatment of COVID-19 after the first patient with an infection with SARS-CoV-2 in the Netherlands was diagnosed in February 2020. On the basis of limited data, at first only off-label use of (hydroxy)chloroquine seemed to be a treatment option. However, now based on the findings of several randomized studies, other medicines have been included in the Dutch guidelines about the treatment of COVID-19. In this article, we will briefly discuss the current state of affairs with regard to the drugs (hydroxy) chloroquine, remdesivir and corticosteroids. Again, it appears that only well-executed randomized clinical trials can determine the status of various supposedly effective drugs.
PubMed: 33331727
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[The medicinal treatment of COVID-19: a brief update].</title><author><name sortKey="De Boer, Mark G J" sort="De Boer, Mark G J" uniqKey="De Boer M" first="Mark G J" last="De Boer">Mark G J. De Boer</name><affiliation wicri:level="3"><nlm:affiliation>LUMC, afd. Infectieziekten, Leiden.</nlm:affiliation><country>Pays-Bas</country><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName><wicri:orgArea>LUMC, afd. Infectieziekten</wicri:orgArea></affiliation><affiliation><nlm:affiliation>Contact: Mark G.J. de Boer (m.g.j.de_boer@lumc.nl).</nlm:affiliation><wicri:noCountry code="no comma">Contact: Mark G.J. de Boer (m.g.j.de_boer@lumc.nl).</wicri:noCountry><wicri:noCountry code="no comma">Contact: Mark G.J. de Boer (m.g.j.de_boer@lumc.nl).</wicri:noCountry></affiliation></author><author><name sortKey="Gieling, Emilie M" sort="Gieling, Emilie M" uniqKey="Gieling E" first="Emilie M" last="Gieling">Emilie M. Gieling</name><affiliation wicri:level="3"><nlm:affiliation>UMC Utrecht, afd. Klinische Farmacie, Utrecht.</nlm:affiliation><country>Pays-Bas</country><placeName><settlement type="city">Utrecht</settlement><region nuts="2" type="province">Utrecht (province)</region></placeName><wicri:orgArea>UMC Utrecht, afd. Klinische Farmacie</wicri:orgArea></affiliation></author><author><name sortKey="Van Der Linden, Paul D" sort="Van Der Linden, Paul D" uniqKey="Van Der Linden P" first="Paul D" last="Van Der Linden">Paul D. Van Der Linden</name><affiliation><nlm:affiliation>Tergooi, afd. Klinische Farmacie, Hilversum.</nlm:affiliation><wicri:noCountry code="subField">Hilversum</wicri:noCountry></affiliation></author><author><name sortKey="Sinha, Bhanu N M" sort="Sinha, Bhanu N M" uniqKey="Sinha B" first="Bhanu N M" last="Sinha">Bhanu N M. Sinha</name><affiliation wicri:level="3"><nlm:affiliation>UMCG, afd. Medische Microbiologie en Infectiepreventie, Groningen.</nlm:affiliation><country>Pays-Bas</country><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName><wicri:orgArea>UMCG, afd. Medische Microbiologie en Infectiepreventie</wicri:orgArea></affiliation></author><author><name sortKey="Vollaard, Albert M" sort="Vollaard, Albert M" uniqKey="Vollaard A" first="Albert M" last="Vollaard">Albert M. Vollaard</name><affiliation><nlm:affiliation>RIVM, Centrum Infectieziektebestrijding, Bilthoven.</nlm:affiliation><wicri:noCountry code="subField">Bilthoven</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:33331727</idno><idno type="pmid">33331727</idno><idno type="wicri:Area/Main/Corpus">000655</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000655</idno><idno type="wicri:Area/Main/Curation">000655</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000655</idno><idno type="wicri:Area/Main/Exploration">000655</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[The medicinal treatment of COVID-19: a brief update].</title><author><name sortKey="De Boer, Mark G J" sort="De Boer, Mark G J" uniqKey="De Boer M" first="Mark G J" last="De Boer">Mark G J. De Boer</name><affiliation wicri:level="3"><nlm:affiliation>LUMC, afd. Infectieziekten, Leiden.</nlm:affiliation><country>Pays-Bas</country><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName><wicri:orgArea>LUMC, afd. Infectieziekten</wicri:orgArea></affiliation><affiliation><nlm:affiliation>Contact: Mark G.J. de Boer (m.g.j.de_boer@lumc.nl).</nlm:affiliation><wicri:noCountry code="no comma">Contact: Mark G.J. de Boer (m.g.j.de_boer@lumc.nl).</wicri:noCountry><wicri:noCountry code="no comma">Contact: Mark G.J. de Boer (m.g.j.de_boer@lumc.nl).</wicri:noCountry></affiliation></author><author><name sortKey="Gieling, Emilie M" sort="Gieling, Emilie M" uniqKey="Gieling E" first="Emilie M" last="Gieling">Emilie M. Gieling</name><affiliation wicri:level="3"><nlm:affiliation>UMC Utrecht, afd. Klinische Farmacie, Utrecht.</nlm:affiliation><country>Pays-Bas</country><placeName><settlement type="city">Utrecht</settlement><region nuts="2" type="province">Utrecht (province)</region></placeName><wicri:orgArea>UMC Utrecht, afd. Klinische Farmacie</wicri:orgArea></affiliation></author><author><name sortKey="Van Der Linden, Paul D" sort="Van Der Linden, Paul D" uniqKey="Van Der Linden P" first="Paul D" last="Van Der Linden">Paul D. Van Der Linden</name><affiliation><nlm:affiliation>Tergooi, afd. Klinische Farmacie, Hilversum.</nlm:affiliation><wicri:noCountry code="subField">Hilversum</wicri:noCountry></affiliation></author><author><name sortKey="Sinha, Bhanu N M" sort="Sinha, Bhanu N M" uniqKey="Sinha B" first="Bhanu N M" last="Sinha">Bhanu N M. Sinha</name><affiliation wicri:level="3"><nlm:affiliation>UMCG, afd. Medische Microbiologie en Infectiepreventie, Groningen.</nlm:affiliation><country>Pays-Bas</country><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName><wicri:orgArea>UMCG, afd. Medische Microbiologie en Infectiepreventie</wicri:orgArea></affiliation></author><author><name sortKey="Vollaard, Albert M" sort="Vollaard, Albert M" uniqKey="Vollaard A" first="Albert M" last="Vollaard">Albert M. Vollaard</name><affiliation><nlm:affiliation>RIVM, Centrum Infectieziektebestrijding, Bilthoven.</nlm:affiliation><wicri:noCountry code="subField">Bilthoven</wicri:noCountry></affiliation></author></analytic><series><title level="j">Nederlands tijdschrift voor geneeskunde</title><idno type="eISSN">1876-8784</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine Monophosphate (analogs & derivatives)</term><term>Adenosine Monophosphate (pharmacology)</term><term>Adenosine Monophosphate (therapeutic use)</term><term>Alanine (analogs & derivatives)</term><term>Alanine (pharmacology)</term><term>Alanine (therapeutic use)</term><term>Anti-Inflammatory Agents (pharmacology)</term><term>Anti-Inflammatory Agents (therapeutic use)</term><term>Antiviral Agents (pharmacology)</term><term>Antiviral Agents (therapeutic use)</term><term>COVID-19 (drug therapy)</term><term>COVID-19 (epidemiology)</term><term>Drug Repositioning (methods)</term><term>Drug Repositioning (standards)</term><term>Glucocorticoids (pharmacology)</term><term>Glucocorticoids (therapeutic use)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (pharmacology)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Netherlands (epidemiology)</term><term>Randomized Controlled Trials as Topic (MeSH)</term><term>SARS-CoV-2 (drug effects)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>AMP (analogues et dérivés)</term><term>AMP (pharmacologie)</term><term>AMP (usage thérapeutique)</term><term>Alanine (analogues et dérivés)</term><term>Alanine (pharmacologie)</term><term>Alanine (usage thérapeutique)</term><term>Anti-inflammatoires (pharmacologie)</term><term>Anti-inflammatoires (usage thérapeutique)</term><term>Antiviraux (pharmacologie)</term><term>Antiviraux (usage thérapeutique)</term><term>Essais contrôlés randomisés comme sujet (MeSH)</term><term>Glucocorticoïdes (pharmacologie)</term><term>Glucocorticoïdes (usage thérapeutique)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (pharmacologie)</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Pays-Bas (épidémiologie)</term><term>Repositionnement des médicaments (méthodes)</term><term>Repositionnement des médicaments (normes)</term><term>Résultat thérapeutique (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adenosine Monophosphate</term><term>Alanine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adenosine Monophosphate</term><term>Alanine</term><term>Anti-Inflammatory Agents</term><term>Antiviral Agents</term><term>Glucocorticoids</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adenosine Monophosphate</term><term>Alanine</term><term>Anti-Inflammatory Agents</term><term>Antiviral Agents</term><term>Glucocorticoids</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Netherlands</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>AMP</term><term>Alanine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Repositioning</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Repositionnement des médicaments</term></keywords><keywords scheme="MESH" qualifier="normes" xml:lang="fr"><term>Repositionnement des médicaments</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>AMP</term><term>Alanine</term><term>Anti-inflammatoires</term><term>Antiviraux</term><term>Glucocorticoïdes</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Drug Repositioning</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>AMP</term><term>Alanine</term><term>Anti-inflammatoires</term><term>Antiviraux</term><term>Glucocorticoïdes</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Pays-Bas</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Randomized Controlled Trials as Topic</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Essais contrôlés randomisés comme sujet</term><term>Humains</term><term>Résultat thérapeutique</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Pays-Bas</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Much has changed in the medical treatment of COVID-19 after the first patient with an infection with SARS-CoV-2 in the Netherlands was diagnosed in February 2020. On the basis of limited data, at first only off-label use of (hydroxy)chloroquine seemed to be a treatment option. However, now based on the findings of several randomized studies, other medicines have been included in the Dutch guidelines about the treatment of COVID-19. In this article, we will briefly discuss the current state of affairs with regard to the drugs (hydroxy) chloroquine, remdesivir and corticosteroids. Again, it appears that only well-executed randomized clinical trials can determine the status of various supposedly effective drugs.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">33331727</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1876-8784</ISSN><JournalIssue CitedMedium="Internet"><Volume>164</Volume><PubDate><Year>2020</Year><Month>11</Month><Day>12</Day></PubDate></JournalIssue><Title>Nederlands tijdschrift voor geneeskunde</Title><ISOAbbreviation>Ned Tijdschr Geneeskd</ISOAbbreviation></Journal><ArticleTitle>[The medicinal treatment of COVID-19: a brief update].</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">D5620</ELocationID><Abstract><AbstractText>Much has changed in the medical treatment of COVID-19 after the first patient with an infection with SARS-CoV-2 in the Netherlands was diagnosed in February 2020. On the basis of limited data, at first only off-label use of (hydroxy)chloroquine seemed to be a treatment option. However, now based on the findings of several randomized studies, other medicines have been included in the Dutch guidelines about the treatment of COVID-19. In this article, we will briefly discuss the current state of affairs with regard to the drugs (hydroxy) chloroquine, remdesivir and corticosteroids. Again, it appears that only well-executed randomized clinical trials can determine the status of various supposedly effective drugs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Boer</LastName><ForeName>Mark G J</ForeName><Initials>MGJ</Initials><AffiliationInfo><Affiliation>LUMC, afd. Infectieziekten, Leiden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Contact: Mark G.J. de Boer (m.g.j.de_boer@lumc.nl).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gieling</LastName><ForeName>Emilie M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>UMC Utrecht, afd. Klinische Farmacie, Utrecht.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Linden</LastName><ForeName>Paul D</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Tergooi, afd. Klinische Farmacie, Hilversum.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinha</LastName><ForeName>Bhanu N M</ForeName><Initials>BNM</Initials><AffiliationInfo><Affiliation>UMCG, afd. Medische Microbiologie en Infectiepreventie, Groningen.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vollaard</LastName><ForeName>Albert M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>RIVM, Centrum Infectieziektebestrijding, Bilthoven.</Affiliation></AffiliationInfo></Author></AuthorList><Language>dut</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Medicamenteuze behandeling van COVID-19.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Ned Tijdschr Geneeskd</MedlineTA><NlmUniqueID>0400770</NlmUniqueID><ISSNLinking>0028-2162</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber><NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>415SHH325A</RegistryNumber><NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="Y">Drug Repositioning</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="Y">Glucocorticoids</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="Y">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>17</Day><Hour>8</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33331727</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Pays-Bas</li></country><region><li>Groningue (province)</li><li>Hollande-Méridionale</li><li>Utrecht (province)</li></region><settlement><li>Groningue</li><li>Leyde</li><li>Utrecht</li></settlement></list><tree><noCountry><name sortKey="Van Der Linden, Paul D" sort="Van Der Linden, Paul D" uniqKey="Van Der Linden P" first="Paul D" last="Van Der Linden">Paul D. Van Der Linden</name><name sortKey="Vollaard, Albert M" sort="Vollaard, Albert M" uniqKey="Vollaard A" first="Albert M" last="Vollaard">Albert M. Vollaard</name></noCountry><country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="De Boer, Mark G J" sort="De Boer, Mark G J" uniqKey="De Boer M" first="Mark G J" last="De Boer">Mark G J. De Boer</name></region><name sortKey="Gieling, Emilie M" sort="Gieling, Emilie M" uniqKey="Gieling E" first="Emilie M" last="Gieling">Emilie M. Gieling</name><name sortKey="Sinha, Bhanu N M" sort="Sinha, Bhanu N M" uniqKey="Sinha B" first="Bhanu N M" last="Sinha">Bhanu N M. Sinha</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000918 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000918 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33331727
|texte= [The medicinal treatment of COVID-19: a brief update].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33331727" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |